Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Kidney transplantation Stories

2014-01-08 12:30:01

HORSHOLM, Denmark, Jan. 8, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/167,420, a patent which covers the diurnal-independent administration of Envarsus(®). The subject patent covers a method of administering Envarsus(®), Veloxis' once-daily formulation of tacrolimus employing the company's proprietary MeltDose(®)...

2013-12-30 04:20:18

HORSHOLM, Denmark, Dec. 30, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus(®) (formerly LCP-Tacro(TM)) for the prevention of organ rejection in kidney transplant recipients. The submission is based on the entire data set from the company's clinical development program that comprised 25 studies and...

2013-12-27 00:21:38

WASHINGTON, Dec. 27, 2013 /PRNewswire-USNewswire/ -- Following is the daily "Profile America" feature from the U.S. Census Bureau: (Logo: http://photos.prnewswire.com/prnh/20110428/DC91889LOGO) GIFT OF LIFE Profile America -- Friday, December 27th. The first successful organ transplant in the U.S. was performed this month in 1954 in Boston by Harvard's Dr. Joseph Murray, who passed away just last year. He transplanted a kidney from one identical twin to another, who lived just over...

2013-12-24 08:23:55

HORSHOLM, Denmark, Dec. 24, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus(® )was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. Envarsus(®) is Veloxis' once-daily formulation of tacrolimus...

2013-12-11 23:24:08

MarketResearchReports.Biz announces addition of new report “Global Kidney Transplantation Clinical Trials Review 2013” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/kidney-transplantation-global-clinical-trials-review-h2-2013. Albany, NY (PRWEB) December 11, 2013 Kidney Transplantation Global Clinical Trials Review, H2, 2013 Clinical trial report, "Kidney Transplantation Global Clinical Trials Review, H2, 2013" provides data on the Kidney...

2013-12-11 08:30:33

HORSHOLM, Denmark, Dec. 11, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced dosing of the first patient in ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of ENVARSUS® (formerly LCP Tacro(TM)) in kidney transplant recipients. The ASERTAA study is designed to compare the pharmacokinetics (PK) of ENVARSUS®, a once-daily tacrolimus tablet, to generic twice daily tacrolimus capsules in stable African-American renal...

2013-11-27 23:32:56

An aging US population and inelastic demand will drive industry growth. For this reason, industry research firm IBISWorld has added a report on the Dialysis Centers industry to its growing industry report collection. Los Angeles, CA (PRWEB) November 26, 2013 Dialysis centers are the lifeblood of patients with chronic kidney disease. Dialysis centers provide valuable services to patients with failing kidneys, but unfortunately, dialysis does not cure kidney disease. This treatment helps...

2013-11-21 13:04:03

Genomic analysis of transplant patients finds an opportunistic microorganism whose elevated presence could be used an indicator in treatment More than 260,000 Americans are alive today thanks to transplant operations that have replaced their failing kidneys, hearts, lungs or livers with healthy organs donated by volunteers or accident victims. But treatment doesn't end with surgery. Transplant recipients follow strict drug regimens designed to suppress their immune systems just enough...

2013-11-19 16:26:00

Senate Bill 850 reported out of Senate Judiciary Committee HARRISBURG, Pa., Nov. 19, 2013 /PRNewswire/ -- "The Donate Life PA Act" (Senate Bill 850/ House Bill 30) was reported out of the Senate Judiciary Committee today and now moves to the full State Senate. The bill includes provisions to educate students in medical and nursing schools, high schools and colleges to create more awareness about organ donation, reinforces that organ transplantation is a priority over other uses of...

2013-11-18 08:29:47

Expanding Paired Donation and IT Platform TOTOWA, N.J., Nov. 18, 2013 /PRNewswire/ -- BiologicTx(®) announced today the recent acquisition of Silverstone Solutions, Inc. and their Kidney Paired Donation software, Silverstone Matchgrid, as part of their continuing expansion. Silverstone Matchgrid is a sophisticated proprietary software application that assists clinicians in accurately matching individuals awaiting kidney transplants with viable living kidney donors who are...


Latest Kidney transplantation Reference Libraries

2011-01-05 16:14:54

The BK virus, a member of the polyomavirus family, has no major consequences of infected except with those that are immunocomprimised or immunosuppressed. The virus was first isolated in 1971 from the urine sample of a renal transplant patient whose initials were B.K. Similar in genome sequences to the JCV virus they are most easily identified and differentiated from each other through serological tests using specific antibodies or through PCR based genotyping approach. Most people are...

More Articles (1 articles) »